Abel E Moreyra

US Patent:

20120282359, Nov 8, 2012

Filed:

Apr 25, 2012

Appl. No.:

13/455595

Inventors:

Abel Ennio Moreyra - Piscataway NJ, US
Ashraf M. Koraym - East Brunswick NJ, US
Alan Chaney Wilson - North Brunswick NJ, US
Owen Rickford Carryl - Mason OH, US

International Classification:

A61K 36/68
A61K 31/215
A61P 3/00
A61K 31/702
A61K 36/899
A61K 31/366
A61K 31/40

US Classification:

424738, 514460, 514510, 514423, 514 54, 424750

Abstract:

Disclosed herein are methods of treating a condition associated with elevated cholesterol levels are provided, comprising administering to a mammal in need of such treatment a safe and effective amount of a cholesterol biosynthesis inhibitor and a soluble fiber. Further disclosed herein are kits comprising a first composition comprising a cholesterol biosynthesis inhibitor selected from the group consisting of HMG CoA reductase inhibitors, HMG CoA synthase inhibitors, and mixtures thereof; and a second composition comprising a soluble fiber. Even further described are compositions comprising a cholesterol biosynthesis inhibitor selected from the group consisting of HMG CoA reductase inhibitors, HMG CoA synthase inhibitors, and mixtures thereof; and a soluble fiber.

US Patent:

20050250734, Nov 10, 2005

Filed:

Nov 2, 2004

Appl. No.:

10/979329

Inventors:

Abel Moreyra - Piscataway NJ, US
Ashraf Koraym - East Brunswick NJ, US
Alan Wilson - North Brunswick NJ, US
Owen Carryl - Mason OH, US

Assignee:

The Procter & Gamble Company - Cincinnati OH

International Classification:

A61K031/715
A61K031/401
A61K031/366
A61K031/225

US Classification:

514054000, 514423000, 514460000, 514548000

Abstract:

Disclosed herein are methods of treating a condition associated with elevated cholesterol levels are provided, comprising administering to a mammal in need of such treatment a safe and effective amount of a cholesterol biosynthesis inhibitor and a soluble fiber. Further disclosed herein are kits comprising a first composition comprising a cholesterol biosynthesis inhibitor selected from the group consisting of HMG CoA reductase inhibitors, HMG CoA synthase inhibitors, and mixtures thereof; and a second composition comprising a soluble fiber. Even further described are compositions comprising a cholesterol biosynthesis inhibitor selected from the group consisting of HMG CoA reductase inhibitors, HMG CoA synthase inhibitors, and mixtures thereof; and a soluble fiber.